Stockscreener 앱 받기
74.84
2.27%
1.66
시장 영업 전:
77.00
2.16
+2.89%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates - Yahoo Finance
B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With 295+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky - PR Newswire
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Nektar Therapeutics (NKTR) and Eos Energy Enterprises, Inc. (EOSE) - Carroll County Mirror-Democrat
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Nektar Therapeutics (NKTR) and Eos Energy Enterprises, Inc. (EOSE) - GlobeNewswire Inc.
Nektar Therapeutics (NKTR) Receives New 'Buy' Rating from TD Cowen | NKTR Stock News - GuruFocus
Should Mixed Q4 Results and REZOLVE-AA Lawsuits Reshape Nektar Therapeutics’ (NKTR) Rezpegaldesleukin-Focused Strategy? - simplywall.st
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at TD Cowen - MarketBeat
Nektar Therapeutics stock initiated with buy rating at TD Cowen By Investing.com - Investing.com India
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $165 - 富途牛牛
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Nektar Therapeutics stock initiated with buy rating at TD Cowen - Investing.com
TD Cowen Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider
Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline - National Today
Nektar Therapeutics (NKTR) Analyst Rating Update: Citigroup Rais - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $123.00 at Citigroup - MarketBeat
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action - The AI Journal
Wall Street experts project a potential 77.28% increase for Nektar (NKTR): Is such a surge in the stock truly achievable? - Bitget
NKTR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $123 - 富途牛牛
Farallon Capital Management LLC Invests $45.01 Million in Nektar Therapeutics $NKTR - MarketBeat
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
NKTR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (2026-03-15) - Seeking Alpha
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - The Norfolk Daily News
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
22NW LP Increases Stock Holdings in Nektar Therapeutics $NKTR - MarketBeat
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals - simplywall.st
Analysts Offer Insights on Healthcare Companies: Agilent (A), Natera (NTRA) and Nektar Therapeutics (NKTR) - The Globe and Mail
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar - GlobeNewswire
Quinn Opportunity Partners LLC Purchases Shares of 109,868 Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics stock hits 52-week high at 76.3 USD By Investing.com - Investing.com South Africa
Decoding Nektar Therapeutics (NKTR): A Strategic SWOT Insight - GuruFocus
Nektar Therapeutics jumps on Q4 results - MSN
Nektar Therapeutics Bets Big on Respag Phase 3 - TipRanks
Nektar Therapeutics (NKTR) Q3 Losses Narrow To US$35.5 Million Testing Bearish Narratives - simplywall.st
Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026 - Meyka
Class Action Lawsuit Announced for Nektar Therapeutics - Intellectia AI
Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters phase III in atopic dermatitis - MSN
Oppenheimer raises Nektar Therapeutics price target to $140 By Investing.com - Investing.com Australia
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar - GlobeNewswire
Oppenheimer raises Nektar Therapeutics price target to $140 - Investing.com India
NKTR (NASDAQ) director sells proposed 78,510 shares via Fidelity - Stock Titan
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer - StreetInsider
Nektar Therapeutics stock hits 52-week high at 76.3 USD - Investing.com Nigeria
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus - Yahoo Finance
Nektar Therapeutics (NKTR) Surges After Beating Q4 Expectations - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 12-Month High Following Earnings Beat - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):